"I guess it just continues to *elude* me that I can't
"I guess it just continues to *elude* me that I can't expect "seamless" from a start-up rolling out such staggeringly valuable tech..."
That's exactly right. The story was pitched by PTOI that the catalyst could be put into pyrolysis and suddenly pyrolysis of plastic could make oil for under $10/bbl which could be sold for WTI-$3...or at about 90% gross margins. Plastic goes in, valuable oil comes out. That was the story told to investors by Mr. Bordynuik and PTOI. With those margins, it should be relatively seemless.
A proof-of-concept takes little time...a couple of months to get everything set up at the most. Mr. Bordynuik pretended to do that with his 1-ton processor and through testing of processor #1 when he was very clear in announcing to shareholders that this fully-tested process can make oil for under $10/bbl for which he said he had offers in hand to buy for WTI-$3 from Somerset and another offer from American Refinery Group and other "refineries". The problem: Mr. Bordynuik flat out lied. Mr. Bordynuik is an honest-to-goodness run-of-the-mill penny stock swindler.
Now over five years of bad luck and delays in trying to shove plastic into a processor?? It's a little hard to swallow that the excuses we keep hearing are the real reason. In late 2010 Mr. Bordynuik even said he was in full commercial production...and let investors think that for all of 2011 after which he finally announced that he decided to keep the processor off line for 'enhancements' to double the throughput. Investors oddlly didn't bat an eye that an $80,000 processor which should have been producing $3.6M per year, was purportedly silently taken off line for 'enhancements' for an entire year. In a real world situation, nobody would dare try to 'improve' a running machine making an almost 50,000% ROI...such a machine would pay for itself in eight days. If the numbers told to investors were real, any company would be smart enough to simply replicate the resounding success.
Plastic2Oil, Inc. (PTOI) Stock Research Links
Yes, I understand your penny stock also is the real deal, created with the inventiveness of Edison and destined to be the next Microsoft. Yes, I understand that the delays are also only because your company is making their product and/or technology even more revolutionary.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Cats Only: Not Just Another Vet Office Sometimes, a new kind of passion-driven initiative gets your attention. That's where CatsOnly™ steps in—a feline-exclusive clinic that’s not about the bottom line but about building connections and elevating that ultimate feline care game. Their latest gig, dubbed Ginger’s Giving Season, is all about bridging the gap between...
Continue Reading
Cracking the Diabetes Code: A New Hope Emerging It ain't every day you hear about a biotech outfit snagging an NIH Fast-Track grant with the potential to upend diabetes treatment, but Paulex Bio's recent score turns heads. Their brainchild, PAL-119, promises to tackle diabetes not by slapping a band-aid on symptoms, but by getting to the rotten core of the disease: the...
Continue Reading
Kia Makes History Well, folks, Kia has pulled off what many might have thought impossible. They snagged not one, not two, but three of Germany's Golden Steering Wheel awards. That's a real hat trick and a first for any non-European auto brand. With competition hotter than a stolen Tesla, Kia's not just keeping pace but setting it. The Golden Steering Wheel is one of those...
Continue Reading
Is AI the Savior for HVAC Breakdowns? You ever been stuck on a freezing night with a busted heater? It's a classic tale: equipment goes south just when you need it most. But what if someone told you AI could catch HVAC issues before they send you running for the wool socks? Enter Resideo Technologies' latest brainchild, Pro-IQ™ Predict. This isn't some run-of-the-mill...
Continue Reading
What’s Driving Up These Premiums? If you’ve ever felt like your wallet gets lighter every time you pay your insurance premium, welcome to the club. It seems like the cost of insurance in Florida is like a runaway train. But don't just blame the hurricanes. Yeah, they definitely play their part, but there’s a bigger picture lurking behind those price tags. Weather...
Continue Reading
Anticipation Builds for The Dixie Group's Q3 Results Ah, the smell of anticipation in the air—it's earnings season again, folks! For those keeping a keen eye, The Dixie Group, Inc. (OTCQB: DXYN) sets the stage for the big unveil of its 2026 third-quarter results. They're rolling out the red carpet for investors on Thursday, November 12, 2026, at 11:30 a.m. Eastern Time,...
Continue Reading
Staffing Game Changer: Enter Ceipal Ora Folks in the staffing arena, hold onto your hats—Ceipal's rolling out something that could turn the tables. This new AI hotshot, Ceipal Ora, claims to be not just another AI patch on an old coat but the whole new garment itself. It's not just some afterthought glued to a platform; it's the glue holding the operations together,...
Continue Reading
A Patch to Simplify Mealtime Insulin So, it turns out CeQur is stepping up to the plate with their new wearable insulin patch called CeQur Simplicity. They just rolled it out nationally, and it's not your grandmother's insulin delivery method—this one sticks around for a whole week with some nifty up-to-1-unit dosing. If you're shoving insulin needles or pens into your...
Continue Reading
Reflecting on Two Decades of Innovation Yeastar's 20th anniversary summit in Xiamen was no ordinary gathering. It wasn't just about handshakes and business cards. Nope, it was a celebration intertwined with a deeper vision of growth and influence in the UCaaS space that Yeastar has carved out for itself over the years. Here's a company that's been plotting its course for...
Continue Reading
Acknowledging AI's Growing Role in Education Times are changing, and the classroom ain't what it used to be. Enter Otus, a platform that's breaking the mold by bringing artificial intelligence smack dab into K-12 education. They've bagged the 2026 SmartBrief Innovation Award in AI within the Education category. Clocking in at serving nearly 100 school districts, it's...
Continue Reading
Top 5 Most Recently Viewed Articles
Revolutionizing Canine Cancer Care Through Innovation The world of veterinary medicine has seen incredible progress in caring for dogs with cancer. Thrive Pet Healthcare is making significant efforts to improve the quality of care for these pets. Their partnership with FidoCure, a leader in canine oncology, highlights their dedication to helping pet owners access...
Continue Reading
BioAtla to Showcase Innovative Cancer Therapies at Major Events BioAtla, Inc. (Nasdaq: BCAB), a prominent player in the biotechnology sector, focuses on advancing Conditionally Active Biologic (CAB) antibody therapeutics aimed at treating solid tumors. With a commitment to innovation and patient care, the company announced that two of its research abstracts have been...
Continue Reading
Revelation in Gold Exploration Liberty Star Minerals, an innovative exploration company, has recently made headlines with the successful induced polarization (IP) and resistivity testing at the Red Rock Canyon Gold Project. This project is a part of their extensive Hay Mountain Project in southeastern Arizona. These tests are pivotal in the ongoing search for strategic...
Continue Reading
Malibu Boats Wakesetter 23 LSV Triumphs Again Malibu Boats, Inc. (NASDAQ: MBUU) continues to solidify its position as the leader in the watersports boating industry. The iconic Malibu Wakesetter 23 LSV has been awarded the prestigious title of Wakesurf and Wakeboard Boat of the Year for the sixth consecutive year by the WakeWorld Riders Choice Awards. This remarkable...
Continue Reading
Understanding Alto Neuroscience's Legal Challenges Alto Neuroscience, Inc. (NYSE: ANRO) is currently in the spotlight due to a securities fraud class action lawsuit filed on behalf of its investors. The company has faced scrutiny regarding its initial public offering (IPO) and claims that misrepresentations were made about its flagship product, ALTO-100, a treatment...
Continue Reading